LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of what’s to come September 26, 2022 Deadline for filing a motion by lead plaintiff in the class action lawsuit filed on behalf of investors who have purchased or otherwise acquired Enochian Biosciences, Inc. (“Enochian” or the “Company”) NOV securities between January 17, 2018 and June 27, 2022inclusive (the “Collection Period”), including common shares issued by Enochian in a private placement on or about February 16, 2018.

If you have suffered a loss on your Enochian investments or would like to inquire about the possibility of making claims to recover your loss under the federal securities laws, you may submit your contact information at www.glancylaw.com/cases/enochian-biosciences-inc/. You can also contact GPM’s Charles H. Linehan at 310-201-9150, toll free at 888-773-9224, or email at [email protected] to learn more about your rights.

On May 25, 2022, the US Department of Justice announced that Serhat Gumrukcu, the co-founder and inventor of Enochian, had been arrested as part of a murder conspiracy.

As a result of this news, the company’s shares fell $2.17, or 37%, on unusually high trading volume to close at $3.70 per share on May 25, 2022.

On June 1, 2022, Hindenburg Research released a research report alleging, among other things, that the charges related to the murder of Gregory Davis, just days before Gumrukcu was due to defend himself against allegations of fraud related to a deal with Davis. According to the message, “[f]Federal prosecutors argued that the prospective merger deal that eventually resulted in Enochian going public was a prime motive for the murder.” The report also claimed that Gumrukcu, not a licensed physician in any jurisdiction in the world, was guilty of a crime announced charges in the midst of the company’s merger and that he had “diverted tens of millions of dollars in shareholder funds from Enochian to his privately held companies.”